J&J – EHA 2026 Hematology Abstracts

Summary Johnson & Johnson announced more than 30 hematology presentations for EHA 2026, including key datasets from the Phase 3 MonumenTAL-3 and MajesTEC-9 multiple myeloma studies and pivotal Phase 2/3 ENERGY data for IMAAVY in warm autoimmune hemolytic anemia. What Happened J&J disclosed its EHA…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

Astellas / AviadoBio – Gene Therapy Program Sustained via Nonprofit Funding
Samsung Biologics Moves Into Peptide Manufacturing
Boulevard Bio Launches with $65 Million
GSK – $1B SiranBio Oligo Deal